Target Price | $96.88 |
Price | $43.01 |
Potential |
125.25%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $96.88.
This is
125.25%
register free of charge
$185.00
330.13%
register free of charge
$40.00
7.00%
register free of charge
|
|
A rating was issued by 27 analysts: 23 Analysts recommend Sarepta Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
125.25%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 1.90 | 2.58 |
52.97% | 35.57% | |
EBITDA Margin | 11.59% | 9.92% |
154.13% | 14.43% | |
Net Margin | 12.37% | -6.56% |
128.69% | 153.04% |
24 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.18 | -1.72 |
137.59% | 178.90% | |
P/E | negative | |
EV/Sales | 1.88 |
21 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Scotiabank |
Locked
➜
Locked
|
Locked | Jun 06 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 22 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | May 20 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | May 08 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 07 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | May 07 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 07 2025 |
Analyst Rating | Date |
---|---|
Locked
Scotiabank:
Locked
➜
Locked
|
Jun 06 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 22 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
May 20 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
May 08 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 07 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 07 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.